Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-03

AUTHORS

Antonio C. Buzaid, David S. Alberts, Janine Eispahr, Kurt Mosley, Yei-Mei Peng, Kendra Tutsch, Collin P. Spears, Harinder S. Garewal

ABSTRACT

Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU). We evaluated in vitro and clinically the effects of adding DP to fluorodeoxyuridine (FUDR) in colorectal cancer. Using a human colony-forming assay, we observed that 0.05 microM DP increased the cytotoxicity of FUDR by a median of 33.5-fold vs 1.5-fold for 5FU against human colon-cancer cell lines. The mechanism of the DP-enhanced antitumor activity of FUDR is not completely understood but appears to be related to a profound inhibition by DP of thymidine accumulation in and FUDR efflux from colon-cancer cell lines. On the basis of these in vitro results, 28 patients with metastatic colon cancer were entered in a clinical trial of monthly courses of 0.1 mg/kg FUDR daily for 14 days and 75 mg oral DP 5 times daily for 14 days starting on the 3rd day of continuous i.v. FUDR infusion. The pharmacokinetics of DP was studied in three patients; the results showed that 98% of total serum DP was protein-bound and that free DP levels were significantly lower than the concentrations necessary for the expected in vitro DP/FUDR modulation. Treatment was well tolerated, with only 12 patients developing mild to moderate toxicity. Of 27 evaluable patients, 4 achieved a partial response that lasted 2, 3, 5, and 6+ months. This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients. Other means of DP administration, such as i.v., i.a., and i.p. injection, may be required to achieve free DP concentrations necessary for successful biochemical modulation of FUDR in patients. More... »

PAGES

124-130

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00692352

DOI

http://dx.doi.org/10.1007/bf00692352

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010055811

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2532072


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromatography, High Pressure Liquid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dipyridamole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Screening Assays, Antitumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Synergism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Floxuridine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Stem Cell Assay", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buzaid", 
        "givenName": "Antonio C.", 
        "id": "sg:person.01064440442.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064440442.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alberts", 
        "givenName": "David S.", 
        "id": "sg:person.07371164557.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07371164557.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eispahr", 
        "givenName": "Janine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mosley", 
        "givenName": "Kurt", 
        "id": "sg:person.01042764736.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042764736.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peng", 
        "givenName": "Yei-Mei", 
        "id": "sg:person.013647133307.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013647133307.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UW Carbone Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.412639.b", 
          "name": [
            "Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 53792, Madison, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tutsch", 
        "givenName": "Kendra", 
        "id": "sg:person.01010043374.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010043374.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southern California", 
          "id": "https://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Comprehensive Cancer Center, University of Southern California, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spears", 
        "givenName": "Collin P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garewal", 
        "givenName": "Harinder S.", 
        "id": "sg:person.01051026777.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051026777.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3322/canjclin.35.1.19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000902314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005572855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005572855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcp.1040760111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007793060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0304-3835(75)97506-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014601964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(00)81398-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027637302"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197806152982401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049118490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.560061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062631608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078304632", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079469204", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079692360", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079733268", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079996653", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080077857", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081691615", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1984.2.4.282", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081915036"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081983013", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082208170", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-03", 
    "datePublishedReg": "1989-03-01", 
    "description": "Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU). We evaluated in vitro and clinically the effects of adding DP to fluorodeoxyuridine (FUDR) in colorectal cancer. Using a human colony-forming assay, we observed that 0.05 microM DP increased the cytotoxicity of FUDR by a median of 33.5-fold vs 1.5-fold for 5FU against human colon-cancer cell lines. The mechanism of the DP-enhanced antitumor activity of FUDR is not completely understood but appears to be related to a profound inhibition by DP of thymidine accumulation in and FUDR efflux from colon-cancer cell lines. On the basis of these in vitro results, 28 patients with metastatic colon cancer were entered in a clinical trial of monthly courses of 0.1 mg/kg FUDR daily for 14 days and 75 mg oral DP 5 times daily for 14 days starting on the 3rd day of continuous i.v. FUDR infusion. The pharmacokinetics of DP was studied in three patients; the results showed that 98% of total serum DP was protein-bound and that free DP levels were significantly lower than the concentrations necessary for the expected in vitro DP/FUDR modulation. Treatment was well tolerated, with only 12 patients developing mild to moderate toxicity. Of 27 evaluable patients, 4 achieved a partial response that lasted 2, 3, 5, and 6+ months. This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients. Other means of DP administration, such as i.v., i.a., and i.p. injection, may be required to achieve free DP concentrations necessary for successful biochemical modulation of FUDR in patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00692352", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435385", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438836", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2468388", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "name": "Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients", 
    "pagination": "124-130", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00692352"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2fe81e3f443c02651d2199e7b76e933e84bb1c9adfe2491bfbba932a08993e71"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010055811"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2532072"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00692352", 
      "https://app.dimensions.ai/details/publication/pub.1010055811"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91444_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00692352"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'


 

This table displays all metadata directly associated to this object as RDF triples.

227 TRIPLES      21 PREDICATES      59 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00692352 schema:about N05e0f595d9bb4977a4f5a688b7d173a7
2 N0ff3daeacdc549c4a16b990290df6f6b
3 N5f0b61ca6d4a4a54838433122231912e
4 N69a458c6fc254a34afd70f9448571bba
5 N71505ea309ed46b1865a00ba642970fa
6 N82e9abe368a340b39c6d43838dac406d
7 N9d56612bb0ce411788f4db06ff4acac1
8 Na657cbea0ec845b58a6e6ed710aef5d1
9 Nc64c3287ac8840a8a6fa2939a2646790
10 Ncd0a97e5ad0545e39ad264d8ef3c235f
11 Nd402a8d57a71440489a6b91557c2f4dc
12 Nd6b1921cf9c74b249d44698d005d259a
13 Nd7fb891ca8764d2f86b199b931add23c
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N51a0329c688b47e2a6d8786e1da451c2
17 schema:citation https://app.dimensions.ai/details/publication/pub.1078304632
18 https://app.dimensions.ai/details/publication/pub.1079469204
19 https://app.dimensions.ai/details/publication/pub.1079692360
20 https://app.dimensions.ai/details/publication/pub.1079733268
21 https://app.dimensions.ai/details/publication/pub.1079996653
22 https://app.dimensions.ai/details/publication/pub.1080077857
23 https://app.dimensions.ai/details/publication/pub.1081691615
24 https://app.dimensions.ai/details/publication/pub.1081983013
25 https://app.dimensions.ai/details/publication/pub.1082208170
26 https://doi.org/10.1002/jcp.1040760111
27 https://doi.org/10.1016/0006-2952(87)90168-7
28 https://doi.org/10.1016/s0304-3835(75)97506-0
29 https://doi.org/10.1016/s0378-4347(00)81398-5
30 https://doi.org/10.1056/nejm197806152982401
31 https://doi.org/10.1126/science.560061
32 https://doi.org/10.1200/jco.1984.2.4.282
33 https://doi.org/10.3322/canjclin.35.1.19
34 schema:datePublished 1989-03
35 schema:datePublishedReg 1989-03-01
36 schema:description Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU). We evaluated in vitro and clinically the effects of adding DP to fluorodeoxyuridine (FUDR) in colorectal cancer. Using a human colony-forming assay, we observed that 0.05 microM DP increased the cytotoxicity of FUDR by a median of 33.5-fold vs 1.5-fold for 5FU against human colon-cancer cell lines. The mechanism of the DP-enhanced antitumor activity of FUDR is not completely understood but appears to be related to a profound inhibition by DP of thymidine accumulation in and FUDR efflux from colon-cancer cell lines. On the basis of these in vitro results, 28 patients with metastatic colon cancer were entered in a clinical trial of monthly courses of 0.1 mg/kg FUDR daily for 14 days and 75 mg oral DP 5 times daily for 14 days starting on the 3rd day of continuous i.v. FUDR infusion. The pharmacokinetics of DP was studied in three patients; the results showed that 98% of total serum DP was protein-bound and that free DP levels were significantly lower than the concentrations necessary for the expected in vitro DP/FUDR modulation. Treatment was well tolerated, with only 12 patients developing mild to moderate toxicity. Of 27 evaluable patients, 4 achieved a partial response that lasted 2, 3, 5, and 6+ months. This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients. Other means of DP administration, such as i.v., i.a., and i.p. injection, may be required to achieve free DP concentrations necessary for successful biochemical modulation of FUDR in patients.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N3323055bfb364d599bab5ae0cc30b1f7
41 N8ab239d03ca5491c8bbc1946440e50e6
42 sg:journal.1088364
43 schema:name Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients
44 schema:pagination 124-130
45 schema:productId N27d46468bafe4b5f8079f101c7156f6f
46 N2b124c4c1f754984be7aaeb19372726d
47 N40507bb593154999b5116df96d6bfe91
48 N4dcc3298aa7244288ca8428c0b61cfb4
49 N8ca33629be9c4f09b32c0a89b7e1713b
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010055811
51 https://doi.org/10.1007/bf00692352
52 schema:sdDatePublished 2019-04-15T09:01
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher Nf0b148cdf1274689a44ac9cc8a89269e
55 schema:url http://link.springer.com/10.1007/BF00692352
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N05e0f595d9bb4977a4f5a688b7d173a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Drug Synergism
61 rdf:type schema:DefinedTerm
62 N0c2154af7690479a888c2cd4d2cf90d5 schema:affiliation https://www.grid.ac/institutes/grid.42505.36
63 schema:familyName Spears
64 schema:givenName Collin P.
65 rdf:type schema:Person
66 N0ff3daeacdc549c4a16b990290df6f6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Chromatography, High Pressure Liquid
68 rdf:type schema:DefinedTerm
69 N27d46468bafe4b5f8079f101c7156f6f schema:name nlm_unique_id
70 schema:value 7806519
71 rdf:type schema:PropertyValue
72 N2b124c4c1f754984be7aaeb19372726d schema:name dimensions_id
73 schema:value pub.1010055811
74 rdf:type schema:PropertyValue
75 N3323055bfb364d599bab5ae0cc30b1f7 schema:issueNumber 2
76 rdf:type schema:PublicationIssue
77 N4017e94463cd42e79fc9029bef53f103 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
78 schema:familyName Eispahr
79 schema:givenName Janine
80 rdf:type schema:Person
81 N40507bb593154999b5116df96d6bfe91 schema:name readcube_id
82 schema:value 2fe81e3f443c02651d2199e7b76e933e84bb1c9adfe2491bfbba932a08993e71
83 rdf:type schema:PropertyValue
84 N4dcc3298aa7244288ca8428c0b61cfb4 schema:name pubmed_id
85 schema:value 2532072
86 rdf:type schema:PropertyValue
87 N51a0329c688b47e2a6d8786e1da451c2 rdf:first sg:person.01064440442.40
88 rdf:rest N72ac0cb4fd524cafa0fdd821832f1264
89 N5379d22188994955b915c82c03349e12 rdf:first N4017e94463cd42e79fc9029bef53f103
90 rdf:rest N817be89fb39d47fa9c33ca3c5dc9c9d4
91 N5f0b61ca6d4a4a54838433122231912e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Bone Marrow
93 rdf:type schema:DefinedTerm
94 N69a458c6fc254a34afd70f9448571bba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Humans
96 rdf:type schema:DefinedTerm
97 N71505ea309ed46b1865a00ba642970fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Cell Line
99 rdf:type schema:DefinedTerm
100 N72ac0cb4fd524cafa0fdd821832f1264 rdf:first sg:person.07371164557.05
101 rdf:rest N5379d22188994955b915c82c03349e12
102 N817be89fb39d47fa9c33ca3c5dc9c9d4 rdf:first sg:person.01042764736.14
103 rdf:rest Ne3890f134e484af7b94d606da67b4d85
104 N82e9abe368a340b39c6d43838dac406d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Colorectal Neoplasms
106 rdf:type schema:DefinedTerm
107 N8ab239d03ca5491c8bbc1946440e50e6 schema:volumeNumber 25
108 rdf:type schema:PublicationVolume
109 N8ca33629be9c4f09b32c0a89b7e1713b schema:name doi
110 schema:value 10.1007/bf00692352
111 rdf:type schema:PropertyValue
112 N9d56612bb0ce411788f4db06ff4acac1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Clinical Trials as Topic
114 rdf:type schema:DefinedTerm
115 Na397729563e24ee8b50c9dba5c53fb95 rdf:first N0c2154af7690479a888c2cd4d2cf90d5
116 rdf:rest Ndafaa90ed7224e9d80c9af0a1f725a00
117 Na657cbea0ec845b58a6e6ed710aef5d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Dipyridamole
119 rdf:type schema:DefinedTerm
120 Nc64c3287ac8840a8a6fa2939a2646790 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Tumor Cells, Cultured
122 rdf:type schema:DefinedTerm
123 Ncd0a97e5ad0545e39ad264d8ef3c235f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Drug Therapy, Combination
125 rdf:type schema:DefinedTerm
126 Nd1e097a32ec141dca27e3c825a402473 rdf:first sg:person.01010043374.57
127 rdf:rest Na397729563e24ee8b50c9dba5c53fb95
128 Nd402a8d57a71440489a6b91557c2f4dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Floxuridine
130 rdf:type schema:DefinedTerm
131 Nd6b1921cf9c74b249d44698d005d259a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Tumor Stem Cell Assay
133 rdf:type schema:DefinedTerm
134 Nd7fb891ca8764d2f86b199b931add23c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Drug Screening Assays, Antitumor
136 rdf:type schema:DefinedTerm
137 Ndafaa90ed7224e9d80c9af0a1f725a00 rdf:first sg:person.01051026777.13
138 rdf:rest rdf:nil
139 Ne3890f134e484af7b94d606da67b4d85 rdf:first sg:person.013647133307.72
140 rdf:rest Nd1e097a32ec141dca27e3c825a402473
141 Nf0b148cdf1274689a44ac9cc8a89269e schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
147 schema:name Oncology and Carcinogenesis
148 rdf:type schema:DefinedTerm
149 sg:grant.2435385 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00692352
150 rdf:type schema:MonetaryGrant
151 sg:grant.2438836 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00692352
152 rdf:type schema:MonetaryGrant
153 sg:grant.2468388 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00692352
154 rdf:type schema:MonetaryGrant
155 sg:journal.1088364 schema:issn 0344-5704
156 1432-0843
157 schema:name Cancer Chemotherapy and Pharmacology
158 rdf:type schema:Periodical
159 sg:person.01010043374.57 schema:affiliation https://www.grid.ac/institutes/grid.412639.b
160 schema:familyName Tutsch
161 schema:givenName Kendra
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010043374.57
163 rdf:type schema:Person
164 sg:person.01042764736.14 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
165 schema:familyName Mosley
166 schema:givenName Kurt
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042764736.14
168 rdf:type schema:Person
169 sg:person.01051026777.13 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
170 schema:familyName Garewal
171 schema:givenName Harinder S.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051026777.13
173 rdf:type schema:Person
174 sg:person.01064440442.40 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
175 schema:familyName Buzaid
176 schema:givenName Antonio C.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064440442.40
178 rdf:type schema:Person
179 sg:person.013647133307.72 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
180 schema:familyName Peng
181 schema:givenName Yei-Mei
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013647133307.72
183 rdf:type schema:Person
184 sg:person.07371164557.05 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
185 schema:familyName Alberts
186 schema:givenName David S.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07371164557.05
188 rdf:type schema:Person
189 https://app.dimensions.ai/details/publication/pub.1078304632 schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1079469204 schema:CreativeWork
191 https://app.dimensions.ai/details/publication/pub.1079692360 schema:CreativeWork
192 https://app.dimensions.ai/details/publication/pub.1079733268 schema:CreativeWork
193 https://app.dimensions.ai/details/publication/pub.1079996653 schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1080077857 schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1081691615 schema:CreativeWork
196 https://app.dimensions.ai/details/publication/pub.1081983013 schema:CreativeWork
197 https://app.dimensions.ai/details/publication/pub.1082208170 schema:CreativeWork
198 https://doi.org/10.1002/jcp.1040760111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007793060
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/0006-2952(87)90168-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005572855
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/s0304-3835(75)97506-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014601964
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/s0378-4347(00)81398-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027637302
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1056/nejm197806152982401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049118490
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1126/science.560061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062631608
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1200/jco.1984.2.4.282 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081915036
211 rdf:type schema:CreativeWork
212 https://doi.org/10.3322/canjclin.35.1.19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000902314
213 rdf:type schema:CreativeWork
214 https://www.grid.ac/institutes/grid.134563.6 schema:alternateName University of Arizona
215 schema:name Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA
216 Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA
217 Veterans Administration Hospital, 85724, Tucson, AZ, USA
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.412639.b schema:alternateName UW Carbone Cancer Center
220 schema:name Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 53792, Madison, WI, USA
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.42505.36 schema:alternateName University of Southern California
223 schema:name Comprehensive Cancer Center, University of Southern California, 90033, Los Angeles, CA, USA
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
226 schema:name Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, 06510, New Haven, CT, USA
227 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...